ArticlePhysical and engineering sciences in medicine2026
Development of a scientific version TPS workflow for BNCT dosimetry based on DICOM and Monte Carlo engine.
Article in Physical and engineering sciences in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Boron Neutron Capture Therapy (BNCT) is a binary targeted radiotherapy modality that requires accurate dose calculation and treatment plan optimization. In this work, we proposed a scientific version Treatment Planning System (TPS) for BNCT. The proposed TPS is a workflow for research purposes, aiming at dosimetric analysis and plan formulation and not certified for clinical use. The workflow integrates DICOM based voxel phantom reconstruction, automated generation of Monte Carlo program input files, and post-processing of BNCT dose components to enable comparative evaluation of candidate epithermal neutron spectra. Boron pharmacokinetics were incorporated using published concentration to time curves following intravenous bolus administration of Borono-Phenyl-Alanine (BPA). Compound Biological Effectiveness (CBE) factors of BPA were further applied to compute biologically equivalent doses for the tumor, normal brain tissue, and scalp. Two representative intracranial targets were selected to investigate dosimetric differences among four therapeutic beam spectra shaped by different moderator materials and thicknesses. The results indicate that the harder spectrum produced by 45 cm FLUENTAL moderation improves treatment efficiency for deep-seated tumors, whereas the softer spectrum produced by 45 cm MgF
Indexed as
Identifiers
42113441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.